• WedgeWPP IS already the global Sanofi incumbent — this is a DEFEND + EXPAND pitch, not a displace pitch. Mindshare globally + WPP creative agencies on 'Miracles of Science' corporate brand.
• WhyUser brief said 'Sanofi global Publicis Power of One 2018' — this is INCORRECT per public record. WPP/GroupM won Sanofi global media in 2017-2018 review; Mindshare became global media AOR across 60+ countries.
• Who ·

1. W1WPP IS already the global Sanofi incumbent — this is a DEFEND + EXPAND pitch, not a displace pitch. Mindshare globally + WPP creative agencies on 'Miracles of Science' corporate brand.
2. W2Nuvaxovid TW launch 2025 is fresh activation surface — disease awareness + vaccination campaign in TW market
3. W3Adult vaccine awareness (flu seniors, pediatric immunization) — TW family-decision marketing wedge
4. W4Dupixent immunology HCP + patient-support programs in TW — meaningful Rx scope
5. W5Opella consumer health spin-off (Allegra, Dulcolax) is a fresh AOR opportunity — could be pitched separately as the spin-off completes
6. W6Local TW cultural insight for 'Miracles of Science' adaptation — patient story localization

• User brief said 'Sanofi global Publicis Power of One 2018' — this is INCORRECT per public record. WPP/GroupM won Sanofi global media in 2017-2018 review; Mindshare became global media AOR across 60+ countries.
• WPP also added to creative roster alongside Publicis and Havas — multi-shop creative model. WPP is the BIG winner not Publicis.
• Mindshare (WPP/GroupM) is Sanofi global media AOR — exceptions: Japan (Hakuhodo handles consumer health), US (Havas on Rx side).
• Sanofi 2024 corporate brand 'Miracles of Science' was DEVELOPED BY WPP agencies (GCI Health + VML) — strong WPP creative footprint, not Publicis.
• Publicis Health has some Sanofi creative scope but is not dominant — WPP is the lead media holding group.
• Opella consumer health spin-off announced 2024 — Allegra/Dulcolax moving to separate entity, fresh AOR opportunity.
• Sanofi Taiwan launched Nuvaxovid in 2025 — active launch surface area in TW.

• Sanofi Taiwan Country Marketing Lead (name not publicly confirmed)General Manager / Country Lead, Sanofi Taiwan

  since unknown

  Sanofi Taiwan covers Specialty Care (Dupixent immunology, MS, rare disease), General Medicines, Vaccines (flu, pediatric incl. Nuvaxovid launched 2025), and Consumer Healthcare (Allegra, Dulcolax — being divested via Opella spin-off announced 2024). Reports into Sanofi Asia.

  Source ↗

Multi-business: Specialty Care (Dupixent, MS, rare disease), General Medicines, Vaccines (flu, pediatric, Nuvaxovid), Consumer Healthcare (Allegra — being spun out via Opella 2024-2025). WPP-dominant globally since 2017-2018: Mindshare for media (60+ countries), WPP creative agencies (GCI Health, VML) on corporate. TW: active Rx HCP, growing vaccine consumer awareness, OTC Allegra in transition.

• 'We chase the miracles of science so you can chase your dreams' corporate brand2024 · WPP (GCI Health + VML) · Global corporate brand / multi-market

  Sanofi's largest-ever global corporate campaign. Features 6 real patients with autoimmune T1D, MS etc. Rolling out France, China, Germany, US then expanding. WPP-developed.

  Source ↗
• Dupixent immunology growth2024 · WPP / Publicis Health (creative); WPP Mindshare (media) · HCP + patient programs

  Top-3 global pharma growth product; atopic dermatitis + asthma + COPD expansion. Heavy HCP marketing in TW.

  Source ↗
• Nuvaxovid COVID-19 vaccine TW launch2025 · WPP / regional · Launch / disease awareness

  Protein-based COVID-19 vaccine launched in Taiwan 2025 — alternative to mRNA shots, head-to-head tolerability data vs Moderna.

  Source ↗
• Allegra allergy seasonal2024 · Sanofi Consumer Healthcare → Opella spin-off · Seasonal allergy TVC + retail

  Allegra is the flagship OTC allergy brand; spring/summer seasonal TW activation. Note: Sanofi announced Opella consumer health spin-off 2024 — Allegra will move out of Sanofi scope.

  Source ↗

Don't pitch as if WPP is the challenger — WPP is the global incumbent media partner. Don't pitch creative platforms that override 'Miracles of Science' — that's WPP's own work. Don't pitch Allegra/Dulcolax as core Sanofi scope — they're moving to Opella spin-off. Focus on defend + expand within existing WPP relationship, with TW-local activation depth.

• GSK Taiwan (Shingrix vs Sanofi flu vaccines; Trelegy vs respiratory)
• Pfizer Taiwan (Prevenar vs Sanofi pediatric vaccines)
• Novartis Taiwan (immunology)
• AbbVie Taiwan (Humira / Skyrizi vs Dupixent in immunology)
• Bayer Taiwan (consumer health: Allegra vs Aspirin/Bepanthen)

• ? Current Sanofi Taiwan country GM name
• ? Is Mindshare TW the executing buyer or does it route through Mindshare China/SG?
• ? What's the Opella spin-off timeline for Allegra TW — fresh AOR?
• ? What's TW-local creative shop for Nuvaxovid launch and disease-awareness work?